Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Sanofi (SNYNF)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cytokinetics (CYTK – Research Report) and Sanofi (SNYNF – Research Report) with bullish sentiments.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Cytokinetics (CYTK)

Barclays analyst Gena Wang reiterated a Buy rating on Cytokinetics today and set a price target of $82.00. The company’s shares closed last Friday at $56.97.

According to TipRanks.com, Wang is a 3-star analyst with an average return of 3.7% and a 42.1% success rate. Wang covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, BioMarin Pharmaceutical, and Crispr Therapeutics AG. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytokinetics with a $80.64 average price target, a 42.1% upside from current levels. In a report issued on September 22, Morgan Stanley also maintained a Buy rating on the stock with a $65.00 price target.

See the top stocks recommended by analysts >>

Sanofi (SNYNF)

In a report released today, Luisa Hector from Berenberg Bank maintained a Buy rating on Sanofi, with a price target of EUR110.00. The company’s shares closed last Friday at $101.83.

According to TipRanks.com, Hector is a 3-star analyst with an average return of 4.1% and a 60.0% success rate. Hector covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Merck & Company, and AstraZeneca. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sanofi with a $123.28 average price target, a 19.9% upside from current levels. In a report issued on September 22, Bank of America Securities also maintained a Buy rating on the stock with a EUR115.00 price target.

Read More on CYTK:

Disclaimer & DisclosureReport an Issue

• Cytokinetics price target raised to $56 from $52 at BofA
• Promising Trial Results and Safety Profile of Aficamten Boost Cytokinetics’ Stock Outlook
• Promising Data from HFSA and Long-term Efficacy of Aficamten Lead to Buy Rating for Cytokinetics
• Cytokinetics’ Aficamten Shows Superior Efficacy in Phase 3 MAPLE-HCM Trial, Boosting Stock Outlook
• Cytokinetics presents data related to aficamten at HFSA Meeting 2025